You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Harvard Business School
McKesson
Baxter
Boehringer Ingelheim

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

Patent: 8,580,782

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,580,782
Title:Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
Abstract: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or compositions.
Inventor(s): Guzi; Timothy J. (Chatham, NJ), Paruch; Kamil (Garwood, NJ), Dwyer; Michael P. (Scotch Plains, NJ), Labroli; Marc A. (Mount Laurel, NJ), Keertikar; Kartik M. (East Windsor, NJ)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:11/788,856
Patent Claims:see list of patent claims

Details for Patent 8,580,782

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Start Trial Merck Sharp & Dohme Corp. (Rahway, NJ) 2022-09-04 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Merck Sharp & Dohme Corp. (Rahway, NJ) 2022-09-04 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Merck Sharp & Dohme Corp. (Rahway, NJ) 2022-09-04 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Merck Sharp & Dohme Corp. (Rahway, NJ) 2022-09-04 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Merck Sharp & Dohme Corp. (Rahway, NJ) 2022-09-04 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Merck Sharp & Dohme Corp. (Rahway, NJ) 2022-09-04 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Merck
Dow
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.